Caladrius Biosciences (CLBS) PT Raised to $10 at Brookline Capital Markets
- Wall Street ends week positively; S&P 500, Dow hit record highs
- Bitcoin (BTC) Drops 3% as Turkey Bans Cryptocurrency Payments Citing Lack of Regulatory Supervision
- Morgan Stanley (MS) Archegos-Related Loss Appears to be $911M
- Dollar at 4-week low on retreating Treasury yields
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Brookline Capital Markets analyst Kumaraguru Raja raised the price target on Caladrius Biosciences (NASDAQ: CLBS) to $10.00 (from $7.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Seven Group Holdings Limited (SVW:AU) (SVNWF) PT Raised to AUD27.50 at Credit Suisse
- BlueScope Steel Limited (BSL:AU) (BLSFY) PT Raised to AUD22.50 at Credit Suisse
- Cia Brasileira de Distribuicao (PCAR3:BZ) PT Raised to R$39 at Morgan Stanley